Essential Trace Element and Mineral Deficiencies and Cardiovascular Diseases: Facts and Controversies
International Journal of Nutrition and Food Sciences
Volume 6, Issue 2, March 2017, Pages: 53-64
Received: Dec. 28, 2016; Accepted: Jan. 9, 2017; Published: Feb. 4, 2017
Views 3660      Downloads 178
Author
Christopher Edet Ekpenyong, Department of Physiology, Faculty of Basic Medical Sciences, University of Uyo, Uyo, Nigeria
Article Tools
Follow on us
Abstract
Deficiencies of minerals and trace elements are common and widespread, and are associated with adverse cardiovascular endpoints. Emerging evidence indicates that, diet rich in these nutrients constitutes a modifiable lifestyle factor that might reduce the risk of cardiovascular disease (CVD). However, the clinical significance of these nutrients in optimizing cardiovascular health and/or ameliorating cardiovascular pathologies is currently debatable. This review aims to explore evidences in favor or against the role of these nutrients in the pathogenesis, progression, management and endpoints of CVDs, and extend the discussion on some discrepant research findings. Literature search was conducted in PubMed, Medline, Scopus and EMBASE databases on studies published in English between 1963 and 2016 using appropriate terms such as minerals, Trace elements, Chromium, Copper, Iron, Magnesium, Selenium, Manganese, Zinc deficiencies and CVD. Indeed, trace elements and minerals play significant cardio protective roles when they are present in adequate pharmacologic concentrations due to their antioxidant, anti-inflammatory and immune function modulatory activities. The discrepant results recorded in some studies could be due to the effects of several poorly adjusted covariates such as interactions between paired/complementary micronutrients, absence of uniformly accepted cut off values for normal range, individual susceptibility and environmental factors and several methodology inadequacies. Supplementation of these nutrients in pharmacologic doses in high-risk individuals or those with known deficiency states is cardioprotective.
Keywords
Trace Element, Mineral, Heart Disease
To cite this article
Christopher Edet Ekpenyong, Essential Trace Element and Mineral Deficiencies and Cardiovascular Diseases: Facts and Controversies, International Journal of Nutrition and Food Sciences. Vol. 6, No. 2, 2017, pp. 53-64. doi: 10.11648/j.ijnfs.20170602.11
Copyright
Copyright © 2017 Authors retain the copyright of this article.
This article is an open access article distributed under the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
References
[1]
World Health Organization. World Health report, 2000, Geneva: . World Health Organization, 2000.
[2]
Tulchinsky TH. Micronutrient deficiency condition: Global Health Issues. Pub Health Rev 2010; 32 [1]: 243-255.
[3]
Liu M, Li C, Sun R, Zeng Y, Chen S and Zhang P. Vitamin D nutritional status and the risk for cardiovascular disease [Review]. Expt Ther Med 2016; 11 [4]: 1189-1193.
[4]
Fortmann SP, Burda BU, Senger CA, Lin SJ, Whitlock EP. Vitamin and Mineral supplements in the primary prevention of cardiovascular diseases and cancer: An updated systematic evidence review for the U. S preventive services task force. Ann Intern Med 2013; 159 [12]: 824-834.
[5]
Xie D-X, Xiong Y-L, Zeng C, Wei J, Yang T, Li H, Wang Y, Goa S, Li Y, Lei G. association between low dietary zinc and hyperuricemia in middle-aged and older males in China: a cross-sectional study. BMJ 2015; 5: e008637. doi: 10.1136/bmjopen.2015-008637.
[6]
TurnLund JR. Shills ME, Shike M, Ross AC Caballero B, Cousins RJ, eds. Modern Nutrition in Health and Diseases. 10th Ed, Philippians: Lippincott Williams and Wilkins; 2006: 286-299.
[7]
Eijkman C. Nobel Lecture: Antineuritic Vitamin and Beriberi. 1929. Available from URL: http: //nobelprize.org/nobel¬_prizes/medicine/laureates/1929/eijkman-lecture.html [accessed 17 March 2010].
[8]
Anderson RA. Natritional factors influencing the glucose/insulin system: chromium. J Am Coll Nutr 1997; 16 [5]: 404-410.
[9]
Muthayya S, Rah JH, Sugimoto JD, Roos FF, Kraemer K, Black RE. The global Hidden hunger indices and Maps: An Advocacy Tool for Action. Plos ONE/www.plosone.org 2013: 8 [6]; 1-12.
[10]
Salas-Salvadό J, Casas-Agustench P, Salas-Huetos A. Culture and historical aspects of Mediferean nuts with emphasis on their attributed health and nutritional properties. Nutr Metab Cardiovasc Dis [NMCD] 2011; 21: Suppl 1: S1-S6.
[11]
Karalius VP, Zinn D, Wuj, Cao G, Minutti C, Luke A, et al. Prevalence of risk of deficiency and inadequacy of 25-hydroxy vitamin D in US children: NHANES 2003-2006. J Pediatr Endocrinol Metab 2014; 27 [5-6]: 461-466.
[12]
Lopez-Riadura R, Willett WC, Rimm EB Liu S, Satampper MJ, Manson JE et al. Magnesium intake and risk of type-2 diabetes in men and women. Diabetes Care 2004; 27 [1]: 134-140.
[13]
Darnto-Hill I, Webb P, Harvey PWJ, Hunt JM, Dalmiya N, Chopra M, Ball MJ, Bloem MW, De Benoist B. Micronutrient deficiencies and gender: social and economic costs. Am J Clin Nutr 2005; 81 [5]: 1198S-1205S.
[14]
Allen L, deBenoist B, Dary O Hurrell R. Guidelines on food fortification with micronutrients. World Health Organization and food and Agricultural/organization of the United Nations Geneva: World Health Organization, 2006.
[15]
Wiser S, Plessow R, Eichler K, Malek O. Capanzana MV, Agdeppa I, Bruegger U. Burden of micronutrient deficiencies by socio-economic strata in children aged 6 months to 5 years in the Philippines. BMC Public Health 2013; 13”1167. http//www.biomedcentral.com/1471-2458/13/1167.
[16]
Radimer K, Bindewald B, Hughes J, Ervin B, Swanason C, Picciano MF. Dietary supplement use by U. S adults: data from the National Health and Nutrition Examination Survey, 1999-2000. Am J Epidermiol 2004; 160: 339-349
[17]
Houston MC. The role of nutrition and nutraceutical supplements in the treatment of hypertension. World J Cardiol 2014: 6 [2]38-66.
[18]
Gaziano JM. Vitamin E and cardiovascular disease: observational studies. Ann N Y Acad Sci 2004; 1031 [1]: 280-291.
[19]
Chiplonkar SA, Agte VV, Tarwadi KV, Paknikar KM, Diwate UP. Micronutrient deficiencies as predisposing factors for hypertension in lacto-vegetarian Indian adults. J Am Coll Nutr 2004: 23 [3]; 239–47.
[20]
Rahman, T., Hosen, I., Towhidul Islam, M. M., Shekhar, H. U. Oxidative stress and human. Health Adv Biosci Biotech 2012; 3 [7A]: 997-1019.
[21]
Houston MC. The role of cellular micronutrient analysis, nutraceuticals, vitamins, antioxidants and minerals in the prevention and treatment of hypertension and cardiovascular diseases. Ther Advan Cardiovasc Dis 2010: 4 [3]; 165-183.
[22]
Zeba AN, Delisle HF, Rossier C Renier G. Association of high-sensitivity C-reactive protein with cardiometabolic risk factors and micronutrient deficiencies in adults of Ouagadougou, Burkina Faso. Br J Nutr 2012; 109 [7]: 1266-1275.
[23]
Sung KG, Kang JH, Shin HS. Relationship of cardiovascular risk factors and serum ferritin with C-reactive protein. Arch Med Res 2007; 38 [1]: 121-125.
[24]
Williams MJ, Poulton R, Williams S. Relationship of serum ferritin with cardiovascular risk factors and inflammation in young men and women. Atherosclerosis 2002; 165 [11]: 179-184.
[25]
Vongpatanasin W, Thomas CD, Schwartz R, Cassis LA, Osborne-Lawrence S, Hahner L, Gibson LL, Black S, Samols D, Shaul PW. C-reactive protein causes downregulation of vascular angiotensin subtype 2 receptors and systolic hypertension in mice. Circulation 2007; 115 [8]: 1020-1028.
[26]
Press RI, Geller J, Evans GW. The effect of chromium picolinate on serum cholesterol and apolipoprotein fractions in human subjects. Western J Med 1990; 152 [1]; 41-45.
[27]
Vincent JB, Quest for the molecular mechanism of chromium action and its relationship to diabetes. Nutr Rev 2000; 58 [3pt1]: 67-72.
[28]
Lamson CW, Plasza SM. The safety and efficacy of high-Dose chromium. Alternative Medicine Review 2002; 7 [3]; 218-235.
[29]
Kimura K. Role of essential trace elements in the disturbance of carbohydrate metabolism. Nippon Rinsho 1996; 54 [1]: 79-84.
[30]
Guallar E, Jiménez FJ, Van ’t Veer P, Bode P, Riemersma RA, Gόmez-Aracena J et al. Low toenail chromium concentration and increased risk of nonfatal myocardiac infarction. Am J Epidemiol 2005; 162 [2]: 157-164.
[31]
Rimm EB, Guallar E, Giovannucci E et al. Toenail chromium levels and risk of coronary heart disease among normal and overweight men [Abstract], In: Final program and Abstracts of the 42nd Annual conference on cardiovascular disease epidemiology and prevention, Honolulu, Hawaii, April 23-26, 2002. Dallas, TX: American Heart Association, 2002 P151.
[32]
Rajpathak S, Rimm EB, Li T, Morris JS, Stampfer MJ, Willet WC, et al. Lower toenail chromium in men with diabetes and cardiovascular disease compared with healty men. Diabetes Care 2004: 27 [9]: 2211-6.
[33]
Korpela H, Kumpulainen J, Jussila E, Kemila S, Kaarianen M, Kaariainen T, et al. Effect of selenium supplementation after acute myocardial infarction. Res Commun Chem Pathol Pharmacol 1989; 65: 249-52.
[34]
Newman HA, Lelghton RF, Lanese RR, Freedland NA. Serum chromium and angiographically determined coronary artery disease. Clin Chem 1978; 24 [4]: 541-544.
[35]
Schroeder HA, Nason AP, Tipton IH. Chromium deficiency as a factor in atherosclerosis. J. Chronic Dis 1970; 23 [2]: 123-142.
[36]
International Agency for Research on Cancer [IARC]. Monographs on the evaluation of carcinogenic risks in humans. Chromium, nickel and welding. World Health Organization 1990; 49: 19-527.
[37]
Simonoff M, Llabador Y, Hamon C, Peers AM, Simonoff GN. Low plasma chromium in patients with coronary artery and heart disease. Biol Trace Elem Res 1984; 6 [5]: 431-439.
[38]
Schroeder HA. Serum cholesterol and glucose in rats fed refined and less refined sugars and chromium. J Nutr 1969; 97 [2]: 237-242.
[39]
Abraham JM, Cho L. The homocysteine hypothesis: still relevant to the prevention and treatment of cardiovascular disease? Cleve Clinic J Med 2010; 77 [12]: 911-918.
[40]
Holman RR, Paul SK, Bethel MA, Matthews DR, Neil AW. 10-year follow-up of intensive glucose control in type 2 diabetes. New Engl J Med 2008: swec359 [15]: 1577-1589.
[41]
Watts DL. The nutritional relationships of copper. J Orthomolecular Med 1989; 4 [2]: 99-108.
[42]
Anderson RA. Chromium metabolism and its role in disease process in man. Clin Physiol Biochem 1986; 4: 31-41.
[43]
Soon E, Treacy CM, Toshner MR, MacKenzie-Ross R, Manglam V, Busbridge M, et al. Unexplained iron deficiency in idiopathic and heritable pulmonary arterial hypertension. Thorax 2011; 66: 326–332.
[44]
Ruiter G, Lankhorst S, Boonstra A, Postmus PE, Zweegman S, Westerhof N, et al. Iron deficiency is common in idiopathic pulmonary arterial hypertension. Eur Respir J 2011; 37: 1386–1391.
[45]
van Empel, V. P., Lee, J., Williams, T. J. & Kaye, D. M. Iron deficiency in patients with idiopathic pulmonary arterial hypertension. Heart Lung Circ 2014; 23: 287–292.
[46]
Salonen T, Salonen R, Pentula I, Herranen J, Jauhiainen M, Kantola I et al. Serum fatty acids, apolipoproteins, selenium and vitamin antioxidants and risk of death from coronary artery diseases. AM J Cardiol 1985; 56: 226-231
[47]
Danesh J, Appleby P. Coronary heart disease and iron status: meta-analyses of prospective studies. Circulation 1999; 99: 852-854.
[48]
Zaakouk AM, Hassan MA, Tolba OA. Serum magnesium status among obese children and adolescents. Egypt Pediatr Assoc Gazette 2016; 64 [1]: 32-37.
[49]
Drueke TB, Lacour B, Magnesium homeostasis and disorders of magnesium metabolism. Feehally J, Floege J, Johnson RJ, eds. Comprehensive clinical nephrology. 3rd ed Philadelphia PA: Mosby 2007: 136-138.
[50]
Barbagallo M, Dominguez LJ, and Resniok LM. Magnesium metabolism in hypertension and type 2 diabetes mellitus. AM J. Ther 2007; 14: 375-385.
[51]
Rosanoff A and Seelig MS. Comparison of mechanism and functional effecst of magnesium and statin pharmaceuticals. J Am Coll Nutr 2004; 23: 501s-505s.
[52]
Olatunj and Soladoye AO. S Effect of increased magnesium intake on plasma cholesterol, triglyceride and oxidative stress in alloxan-diabetic rats. Afri J Med Sci 2007.
[53]
Volpe SL. Magnesium, the metabolic syndrome, insulin resistance, and type 2 diabetes mellitus critical reviews in Food Science and Nutrition 2008; 48: 293-300.
[54]
Resnick LM. Cellular ions in hypertension, insulin resistance, obesity, and diabetes: a unifying theme. J Am Soc Nephrol 1992: 3: S78-85.
[55]
Sowers R, Draznin B. Insulin, cation metabolism and insulin resistance. J Basic Clin Physiol Pharmacol 1998; 9: 223-233.
[56]
Guerrero-Romero F, Rodriguez-Moran M. Relationship between serum magnesium levels and C-reactive protein concentration in non-diabetic, non-hypertensive obese subjects. Int J Obes Relat Metab Disord 2002; 26 [4]: 469-474.
[57]
Kim DJ, Xun P, Liu K, Loria C, Yokota K, Jacobs DR Jr et al. Magnesium intake in related to systemic inflammatory, insulin resistance, and the incidence of diabetes. Diabetes Care 2010, 33 [12]: 2604-2010.
[58]
Blache D, Devanx S. Joubert O, Loreau N, Schneider M, Durand P et al. Long-term moderate magnesium-deficient diet shows relationships between blood pressure, inflammation and oxidant stress defense in aging rats. Free Radic Boil Med 2006; 41 [2]: 277-284.
[59]
Wu F, Altura BT, Gao J, Barbour RL, Altura BM. Ferrylmyoglobin formation induced by acute magnesium deficiency in perfused rat heart causes cardiac failure. Biochim Biophys Acta- Mol Basis Dis1994; 1225 [2]: 158-164.
[60]
Altura BM, Altura BT. Magnesium and its role in biology nutrition and physiology. In: Metal ions Biological systems 1990, vol 26 [Sieged, H & Sieged A eds.] pp. 359-416. Marred Dekker, Inc., New York.
[61]
Bo S, Durazzo M, Guidi S, Carello M, Sacerdote C, Silli B et al. Dietary magnesium and eber intakes and inflammatory and metabolic indicators in middle-aged subject from a population-based cohort. Am J Clin Nutr 2006; 84: 1062-69.
[62]
Huerta MG, Roemmich JN, Kington ML, Bovbjerg VE, Wettman AL, Holmes VF et al. Magnesium deficiency is associated with insulin resistance in obese children. Diabetes Care 2005; 28 [5]: 1175-1181.
[63]
Sothern MS, Despinasse B, Brown R, Suskind RM, Udall JN Jr, Blecker U. Lipid profile of obese children and adolescent before and after significant weight loss: differences according to sex. South Med J 2000; 93 [3]: 278-282.
[64]
Joffres MR, Reed Dm, Yano K. relationship of magnesium intake and other dietary factors to blood pressure: the Honolulu heart study. Am J Clin Nutr 1987; 42 [2]: 469-475
[65]
Khan AM, Sullivan L, McCabe E, Levy D, Vasan RS, Wang TJ. Lack of association between serum magnesium and the risks of hypertension and cardiovascular disease. Am Heart J 2010; 160 [4]: 715-20.
[66]
Wexler R, Aukerman G. Nonpharmacologic strategies for managing hypertension. Am Fam Physician 2006; 73 [11]: 1953-6
[67]
Guerrero-Romero F, Rodriguez-Moran M. Relationship between serum magnesium levels and C-reactive protein concentration in non-diabetic, non-hypertensive obese subjects. Int J Obes Relat Metab Disord 2002; 26 [4]: 469-474.
[68]
Zemel, M. B., Reddy, S., Shehin, S., Lockette, W. & Sowers, J. R. [1990] Vascular reactivity in Zucker obese rats. Role of insulin resistance. J Vasc Med Biol 1990; 2: 81–85.
[69]
Jahen-Dechent W and Ketteler M. Magnesium basics. Clin. Kidney J 2012; 5 [Suppl.1]: i3-i14.
[70]
Amiot D, Hioco D, Durlach J. Frequency of magnesium deficit in the normal subjects and in various steopathies. J Med Be-sancon 1969; 5: 371-378.
[71]
Clarkson EM, Warren RL, McDonald SJ, de Wardener HE. The effect of a high intake of calcium on magnesium metabolism in normal subjects and patients with chronic renal failure. Clin Sci 1967; 32: 11-18.
[72]
Chiesi M and Inesi G. Mg2+ and MN2+ modulation of Ca2+ transport and ATPase activity in sarcoplasmic reticulum vesicles. Arch Biochem Biophys 1981; 208: 586-592.
[73]
Gaillard E. Laurant P, Robin S and Berthelot A. Effect of long-term high manganese intake on magnesium metabolism in rats. Magnes-Res 1996; 9119-123.
[74]
Sanchez-Morito N, Planells E, Aranda P, Liopis. Magnesium-manganese interactions caused by magnesium deficiency in rats. J Am Coll Nutr 1999; 18: 475-480.
[75]
Miller KB, Caton JS, Schafer DM, Smith DJ, Finley JW. High Dietary Manganese lowers heart Magnesium in pigs fed a low-magnesium diet. J Nutr 2000; 130: 2032-2035.
[76]
Shamberger RJ, Gunsch MS, Willis CE, McComack LJ [1978]. Selenium in heart disease II. Selenium and other trace metal intake and heart disease in 25 countries in Trace substances in Environmental Health. Vol 12, Hemphill D. D. Ed. University of Missourt Press, Columbia 48.
[77]
Blankenberg S, Rupprecht HJ, Bickel C, Torzewski M, Hafter G, Tiret L, et al. Glutathione peroxidase 1 activity and cardiovascular events in patients with coronary artery disease. N Engl J Med 2003; 349 [17]: 1605-13.
[78]
Nawrot T, Plusquin M, Hogervorst J, Roels HA, Celis H, Thijs L, et al. Environmental exposure to cadmium and risk of cancer: a prospective population-based study. Lancet Oncol 2006; 7 [2]: 119–126.
[79]
Salonen JT, Salonen R, Seppanen K, Kantola M, Parviainen M, Alfthan G, et al. Relationship of serum selenium and antioxidants to plasma lipoproteins, platelet agregability and prevalent ischaemic heart disease in Eastern Finnish men. Atherosclerosis 1988; 70: 155-60.
[80]
Laclaustra M, Navas-Acien A, Stranges S, Ordovas JM, Guallar E. Serum selenium levels and hypertension in the US population. Circ Cardiovasc Qual Outc 2009; 2 [4]: 369-76.
[81]
Brown BG, Zhao XQ, Chait A, Fisher LD, Cheung MC, Morse JS, et al. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med 2001; 345 [22]: 1583-92.
[82]
Kuklinski B, Weissenbacher E, Fahnrich A. Coenzyme Q10 and antioxidants in acute myocardial infarction. Mol Aspects Med 1994; 15: S143-7.
[83]
You WC, Chang YS, Heinrich J, Ma JL, Liu WD, Zhang L, et al. An intervention trial to inhibit the progression of precancerous gastric lesions: compliance, serum micronutrients and S-allyl cysteine levels, and toxicity. Eur J Cancer Prev 2001; 10 [3]: 257-63.
[84]
Hercberg S, Galan P, Preziosi P, Bertrais S, Mennen L, Malvy D, et al. The SU. VI. MAX Study: a randomized, placebo-controlled trial of the health effects of antioxidant vitamins and minerals. Arch Intern Med 2004; 164 [21]: 2335-42.
[85]
Stranges S, Marshall JR, Trevisan M, Natarajan R, Donahue RP, Combs GF, et al. Effects of Selenium Supplementation on Cardiovascular Disease Incidence and Mortality: Secondary Analyses in a Randomized Clinical Trial. Am J Epidemiol 2006; 163: 694-9.
[86]
Toyran N, Turan B, Severcan F. Selenium alters the lipid content and protein profile of rat heart: an FTIR microspectroscope study. Arch Biochem Biophys 2007; 458 [2]: 184-193.
[87]
Duffield AJ, Thomson CD, Hill KE, Willaim S. An estimation of selenium requirements for New Zealanders. Am J Clin Nutr 1999; 70 [5]: 896-903.
[88]
Xia Y, Hill KE, Byrne DW, Xu J, Burk RF. Effectiveness of selenium supplements in a low selenium area of China. Am J Clin Nutr 2005; 81 [4]: 829-34.
[89]
Burk RF, Norsworthy BK, Hill KE, Motley AK, Byrne DW. Effects of chemical form of selenium on plasma biomarkers in a high-dose human supplementation trial. Cancer Epidemiol Biomarkers Prev 2006; 15 [4]: 804-10.
[90]
Combs GF, Jr. Selenium in global food systems. Br J Nutr 2001; 85: 517-47.
[91]
Rayman MP. Food-chain selenium and human health: emphasis on intake. Br J Nutr 2008; 100 [2]: 254-68.
[92]
Bagheri B, Shokrzadeh M, Akbari N, Mokhberi V, Azizi S Khalliian A, et al. The relationship between serum level of manganese and severity of coronary atherosclerosis. Zahedan J Res Med Sci [ZJRMS] 2015; 17 [1]30-33.
[93]
Agata N, Tanaka H, Shigenobu K. Effect of Mn2+ on neonatal and adult rat heart: initial depression and late augmentation of contractile force. Eur J Pharmacol 1992; 222 [2-3]: 223-226.
[94]
Li XG, Zhou XB. Effect of manganese on the electric activity in ventricle muscle and sinus cell. J Chinese Endemic Dis 1987; 6: 67-70.
[95]
Chandra M, Panchatcharam M, Miriyala S. Manganese superoxide dismutase; Guardian of the heart. MOJ Ana Physiol 2015; 1 [2]: 1-2.
[96]
Van Remmen H, Ikeno Y, Hamilton M, Phahlavani M, Wolf N, et al. Life-long reduction in MnSOD activity results in increased DNA damage and higher incidence of cancer but does not accelerate aging. Physiol Genomics 2003: 16 [1]: 29-37.
[97]
Faraci FM, Didion SP. Vascular protection: superoxide dismutase isoforms in the vessel wall. A Aterioscler Thromb Vasc Biol 2004; 8: 1367-1373.
[98]
Barrington WW, Angle CR, Willcockson MA, Korn T. Autonomic function in manganese alloy workers. Environ Res 1998; 78 [1]: 50–3
[99]
Jiang Y, Zheng W. Cardiovascular toxicities upon manganese exposure cardiovasc Toxicol 2005; 5 [4]: 345-354.
[100]
Osredkar J, and Susuatr N. Copper and Zinc, biological role and significant of copper/ zinc imbalance. J Clin Toxicol 2011, S3: 001 doi: 10,4172/2161-0495. S3-001.
[101]
Perry DK, Smyth MJ. Stennicke HR, Salvesen GS, Duriez Poirierz GG, et al. Zinc is a potent inhibitor of the apoptotic protease, caspase-3. A novel target for zinc in the inhibition apoptosis. J Biol Chem 1997; 272: 18530-18533.
[102]
Islamoglu Y, Evliyaoglu O, Tekbas E, Cil H, Elbey M. The relatiohsip between serum levels of zinc and CU, and severity of coronary atherosclerosis. Biol Trace Elem Res 2011; 144 [1-3]: 436-44.
[103]
Ford ES. Serum copper concentration and coronary heart disease among US adults.. Am J Epidemiol 2000; 152: 1182-1188.
[104]
Kazemi-Bajestani SM, Ghayour-Mobarhan M, Ebrahimi M, Moohebati M, Esmaeili HA, Parizadeh MR, Aghacizadeh R, Ferns GA. Serum copper and zinc concentrations are lower in Iranian patients with angiographically defined coronary artery disease than in subjects with a normal angiogram. J Trace Elem Med Biol 2007; 21 [1]: 22-8.
[105]
Tsuboi A, Terazawa Watanabe M, Kazumi T, Fukuo K. Serum copper, zinc and risk factor cardiovascular disease in community-living Japanese elderly women. Asia Pac J Clin Nutr 2014: 23 [2]: 239-245.
[106]
Little PJ, Bhattacharya R, Moreyra AE, Korichneva IL. Zinc and cardiovascular disease. Nutrition 2010; 26: 1050-1057.
[107]
Lee SR, Noh SJ, ProntoJR, Jeong YJ, Kim HK, Song IS, Xu Z, Kwon HY, Kang SC, Sohn E-H, Ko KS, Khee BD, Kim N, Han J. the critical role of zinc: beyond impact on myocardial signaling. Korean J Physiol Pharmacol 2015; 19: 389-399.
[108]
Prasad AS. Zinc is an antioxidant and anti-inflammatory agent: its role in human health. Front Nutr 2014: 1 [14]: 1-10.
[109]
Wong CP, Ho E. Zinc and its role in age-related inflammation and immune dysfunction. Mol Nutr Food Res 2012; 56 [1]: 77-87.
[110]
Trumbo P, Yates AA, Schlicker S, Poos M. Dietary reference intakes: vitamin A, vitamin K, arsenic, boron, chromium, copper, iodine, iron, manganes, magnesium, molybdenum, nickel, silicon vanadium and zinc. J Am Diet Assoc 2001; 101: 294-301.
[111]
Jiang Y, Reynolds C, Xiao C Feng W, Zhou Z, Rodriguez W, Tyagi SC, Eaton JW, Saari JT, Kang YL. Dietary copper supplementation reverses hypertrophic cardiomyopathy induced by chronic pressure overload in mice. J Expt Med 2007; 204 [3]: 657-666.
[112]
Nath R. Copper deficiency and heart disease: molecular basis, recent advances and current concepts. Int J Biochem Cell Biol 1997; 29 [11]: 1245-1254.
[113]
Saari JT. Copper deficiency and cardiovascular disease: role of peroxidation, glycation and nutrition. Canadian J Physiol Pharmacol 2000; 78: 848-855.
[114]
Jalili T, Medeiros DM, Wildman RE. aspect of cardiomyopathy are exacerbated by elevated dietary fat in copper restricted rats. J Nutr 1996; 126: 807-816.
[115]
Prohaska JR, Copper. In: Erdman JW, Macdonald IA, Zeisel SH. Eds. Present knowledge in Nutrition 10th Ed. Anies: Wiley-Blackwell, 2012: 540-553.
[116]
Bode AM, Miller LA, Faber J, Saari JT. Mitochondrial respiration in heart, liver and kidney of copper deficient rats. J Nutr Biochem 1992; 3: 668-672.
[117]
Matz JM, Saari JT, Bode AM. Functional aspect of oxidative phosphorylation and electron transport in cardiac mitochondria of copper-deficient rats. J Nutr Biochem 1995; 6: 644-652.
[118]
Allen KG. Copper and artery, In Role of copper in lipid metabolism. Edited by K. Y. Lei CRC Press: Bocca Raton Flap 1990, p. 201-216.
[119]
Ziche M, Jones J, Gullino PN. Role of prostaglandin E1 and copper in angiogenesis. J Natl Cancer Inst 1982; 69: 475-482.
[120]
Schuschke DA. Dietary copper in the physiology of the microcirculation. J Nutr 1997; 127: 2274-2281.
[121]
Reiser S, Smith JC Jr, Mertz W. Holbrook JT Scholfield DJ, Powell AS, Canfield WK, Canary JJ. Indices of copper status in humans consuming a typical American diet containing either fructose or starch. Am J CLin Nutr 1985; 42: 242-251.
[122]
Papadopoulou LC, Sue CM, Davidson MM, Tanji K, Nishino I, Sadlock JE, et al. Fetal infantile cardio-encephalomyopathy with COX deficiency and mutations in SCO2, a COX assembly gene. Nat Genet 1999; 23: 333-337.
[123]
Witte KKA, Nikitin NP, Parker AC, von Haehling S, Volk HD, Anker SD, Clark AL, Cleland JGF. The effect of micronutrient supplementation on quality-of-life and left ventricular function in elderly patients with chronic heart failure. Eur Heart J 2005; 26: 2238-2244.
[124]
Didion SP, Ryan M, Didion L, Fegan PE, Sigmud CD, Faraci FM. Increased superoxide and vascular dysfunction in CuZnSOD deficient mice. Cir Res 2002; 19: 938-944.
[125]
Leslie AG. Integration of macromolecular diffraction data. Acta Crystallogr D Biol Crystallogr 2006; 62 [pt1]: 48-57.
[126]
Shiojima A, Sato K, Izumiya Y, Schiekofer S, Ho M, Liao RL Colucci WS, Walsh K. Disruption of coordinated cardiac hypertrophy and angiogenesis contributes to the transition to heart failure. J Clin Invets 2005; 115: 2108-2118.
ADDRESS
Science Publishing Group
1 Rockefeller Plaza,
10th and 11th Floors,
New York, NY 10020
U.S.A.
Tel: (001)347-983-5186